Online CME/CPD
levodopa
Online CME:   Log In | Register

Levodopa: The Gold Standard in the Treatment of Parkinson's Disease

Supported through an educational grant from F. Hoffman-LaRoche, Ltd.
Roche

Instructions for Participation
In order to complete this CME Newsletter and receive CME credit, please follow the instructions below. It should take approximately 1.0 hour to successfully complete this activity. This activity must be completed during the period from November 1, 2007, through November 1, 2008.
  • Read the "Levodopa: The Gold Standard in the Treatment of Parkinson's Disease" newsletter.
  • Complete the online post-test and evaluation and submit to the International Secretariat. Please click here to download and print the post-test and evaluation. Please fax the completed forms back to The Movement Disorder Society at +1 414-276-3349.
Please note: Participants must receive a minimum test score of 70% and respond to all evaluation questions to receive a certificate.

After submitting the post-test and activity evaluation, the relevant certificate will be mailed to you, within 3-4 weeks.

The content of this Enduring Educational Activity was derived from The Movement Disorder Society's 10th International Congress of Parkinson's Disease and Movement Disorders.

Accreditation Statement
The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Movement Disorder Society designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
This activity has been designed to meet the educational needs of Movement Disorder specialists, general neurologists, physicians-in-training, and other healthcare professionals interested in the current research and approaches for the diagnosis and treatment of Parkinson's disease.

Learning Objectives
At the conclusion of the activity, participants should be able to:

  1. Know the pros and cons of initiating therapy early with levodopa;
  2. Describe the late complications of levodopa therapy and their mechanisms of causation;
  3. Know which symptoms of Parkinson's disease are dopa responsive and which require alternative therapeutic approaches.

Faculty List with Degrees and Affiliations

Chairs:
Andrew J. Lees, MD, FRCP
London, United Kingdom

Niphon Poungvarin, MD, FRCP
Bangkok, Thailand
Faculty:
Stanley Fahn, MD
New York, New York USA

Eduardo Tolosa, MD
Barcelona, Spain

Privacy / Confidentiality Notice
MDS will collect and store information you provide in this Internet educational activity for the purposes of enabling us to register your participation in the activity, to assist with administrative and planning purposes, for future planning and development of educational offerings and to allow the compilation and analysis of statistics relevant to MDS.

The information that you provide in this Internet educational activity including without limitation any feedback obtained during the activity, will be used by MDS to offer, provide and continue to improve MDS educational offerings and other services.

MDS will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of MDS or where such purpose is permitted or required by law.